Take the omni-focal approach

Article

An omni-focal approach, combining an aspheric prebyopic treatment with a hyperopic ablation, looks promising as a method for improving near vision in hyperopes with presbyopia.

An omni-focal approach, combining an aspheric prebyopic treatment with a hyperopic ablation, looks promising as a method for improving near vision in hyperopes with presbyopia, according to Efekan Coskunseven from the Dunya Eye Hospital, Istanbul, Turkey.

Dr Coskunseven explained that the wavefront-guided treatment is dependent on pupil size and is designed to correct refractive errors, in addition to higher order aberrations. The aspheric ablation algorithm uses a combination of variable spot scanning (VSS), variable repetition rate (VRR), WaveScan aberrometry with Hartmann-Shack and Fourier technology and iris recognition to improve the accuracy of the ablation and to ensure correct placement on the cornea. All treatments were performed using the AMO/VISX Star S4 CustomVue excimer laser.

The global clinical results, so far, suggest that 100% of eyes treated with this system have achieved simultaneous binocular vision of 20/25 distance and J3 near vision by one year follow-up, with very little decline in contrast sensitivity. Dr Coskunseven, in his own case series, found that 90% of eyes achieved a near vision of J3 or better at six months.

Although some patients do experience a decline in distance vision, the loss is considered negligible. Overall, however, the treatment approach is showing promise and longer-term follow-up is required to assess the visual changes more thoroughly.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.